Exact Sciences Misses Revenue Estimates by $1.8 Million -- But It Cost the Company a Lot More

Just a couple of months ago, Exact Sciences (NASDAQ:EXAS) stock was soaring. The American Cancer Society (ACS) changed its guidelines to recommend the minimum age for colorectal cancer screening be lowered from 50 to 45. That was very good news, since Exact Sciences' Cologuard DNA test is one of the colorectal cancer screening methods that the ACS mentions in its guidelines.